AstraZeneca beats by $0.22, beats on revenues

AstraZeneca (NYSE:AZN) Q2 core EPS of $1.30, beats by $0.22.

Core operating profit decline 1% to $2.03B.

Revenue +4% to $6.45B, topping consensus of $6.24B.

The company revised FY14 Core EPS guidance to decrease in low double digits at CER, revenue in line at CER from FY13.

The company declared interim dividend of $0.90.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs